COEP insider buying and SEC filings, explained
Coeptis Therapeutics Holdings, Inc. · CIK 1759186
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 18, 2026 | Open-market purchase Amended filing | Christopher Ryan Schadel (Chief Marketing Officer) bought 1,000 shares at $3.92 ($4K) in an open-market purchase. Holdings up 41% to 3,467 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Aug 20. | SEC filing Filed Oct 2, 2026, 6:49 PM ET |
27 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow COEP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.